Rubric Capital Management (New York)’s Viatris VTRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$453M Buy
33,500,000
+8,000,000
+31% +$112M 4.79% 6
2025
Q4
$317M Buy
25,500,000
+10,115,000
+66% +$109M 3.8% 6
2025
Q3
$152M Buy
15,385,000
+3,385,000
+28% +$32.9M 1.72% 14
2025
Q2
$107M Buy
+12,000,000
New +$101M 1.62% 17
2025
Q1
Sell
-20,144,365
Closed -$251M 79
2024
Q4
$251M Hold
20,144,365
3.22% 6
2024
Q3
$234M Hold
20,144,365
3.81% 6
2024
Q2
$214M Buy
20,144,365
+1,702,272
+9% +$18.8M 5.61% 3
2024
Q1
$220M Buy
18,442,093
+874,201
+5% +$10.5M 6.51% 2
2023
Q4
$190M Buy
17,567,892
+4,317,892
+33% +$41.3M 3.95% 4
2023
Q3
$131M Buy
13,250,000
+1,300,000
+11% +$13.5M 4.9% 4
2023
Q2
$119M Buy
+11,950,000
New +$114M 5.1% 3
2019
Q2
Sell
-1,700,000
Closed -$48.2M 68
2019
Q1
$48.2M Buy
1,700,000
+690,000
+68% +$20.1M 4.5% 2
2018
Q4
$27.7M Buy
+1,010,000
New +$32.7M 3.43% 10

Other funds holding VTRS

Rubric Capital Management (New York)'s VTRS Position: Q1 2026 in Review

Rubric Capital Management (New York) increased its Viatris (VTRS) stake by 31% in Q1 2026, buying an estimated $112M and bringing the position to 33,500,000 shares worth $453M. The position accounts for 4.79% of the portfolio, ranked #6.

Rubric Capital Management (New York) first reported a position in VTRS in Q4 2018 and has held it in 13 quarters since. 1,021 funds tracked by Wall St. Rank hold VTRS as of Q1 2026.

  • Rubric Capital Management (New York) held 33,500,000 shares of Viatris worth $453M as of Q1 2026.
  • Rubric Capital Management (New York) bought 8,000,000 Viatris shares in Q1 2026, an estimated $112M.
  • Viatris made up 4.79% of Rubric Capital Management (New York)'s portfolio in Q1 2026, its #6 holding.
  • Rubric Capital Management (New York) first reported a position in Viatris in Q4 2018 and has held it in 13 quarters since.
  • 1,021 funds tracked by Wall St. Rank held Viatris as of Q1 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2026, filed 15 May 2026.